Impact of Proviral-DNA M184V/I on 96-Week Outcomes of DTG/3TC Maintenance Therapy: Results From the VOLVER Clinical Trial
María Lagarde, Rosa de Miguel, Mayra A Sigcha, José Luis Blanco et autres
BACKGROUND: The effect of archived lamivudine resistance mutations in the efficacy of dolutegravir plus lamivudine (DTG/3TC) remains unclear. We evaluated whether proviral-DNA M184V/I detection is associated with virological outcomes in the VOLVER-GESIDA 11820 study. METHODS: This open-label, single-arm, multicenter phase IIa trial …
es (code pays fourni par la source)
0 citations
Clinical Infectious Diseases